Gastric bypass significantly improves quality of life in morbidly obese patients with type 2 diabetes.

Published

Journal Article

OBJECTIVE: To evaluate the impact of Roux-en-Y gastric bypass (RYGB) on quality of life in obese diabetic patients compared to standard medical therapy for type 2 diabetes mellitus. METHODS: We prospectively studied two matched obese populations with type 2 diabetes. Thirty patients underwent laparoscopic RYGB and 31 received standard medical therapy combined with a diabetes support and education program (DSE), consisting of educational sessions on diet and exercise. Groups were matched by age, gender, weight, glucostatic parameters, and use of glucose-lowering medications (oral agents and insulin therapy). Health-related quality of life (HRQOL) was assessed using the normalized SF-36 questionnaire, and data were collected at baseline and at 12-month follow-up. RESULTS: Diabetic patients who underwent RYGB experienced a statistically significant increase in their overall HRQOL. However, the role-physical and mental health domains increased but did not reach statistical significance. Diabetic patients in the medical therapy and DSE group did not show any significant increase in HRQOL. The between-group differences for the HRQOL changes from baseline were significant, other than for role-physical and mental health domains. Percentage changes in glucostatic parameters, discontinuation of glucose-lowering medications, and T2DM remission were not found to predict the percentage change in SF-36 scores at 12 months after RYGB. CONCLUSIONS: For the first time, with a prospective matched control study, we demonstrate a significant improvement in HRQOL in obese diabetic patients who underwent RYGB, but not in those who were offered standard medical therapy and DSE.

Full Text

Duke Authors

Cited Authors

  • Omotosho, P; Mor, A; Shantavasinkul, PC; Corsino, L; Torquati, A

Published Date

  • July 2016

Published In

Volume / Issue

  • 30 / 7

Start / End Page

  • 2857 - 2864

PubMed ID

  • 26823053

Pubmed Central ID

  • 26823053

Electronic International Standard Serial Number (EISSN)

  • 1432-2218

Digital Object Identifier (DOI)

  • 10.1007/s00464-015-4568-0

Language

  • eng

Conference Location

  • Germany